CellCentric Email Format

Biotechnology ResearchCambridge, United Kingdom11-50 Employees

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.

p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers.

CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers).  These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

✕

Access Insights for CellCentric and Millions of Other Companies

Sign up for full access to CellCentric information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory